BlackRock Global Funds - World Healthscience Fund A2Register to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 10.5 | 15.2 | 6.7 | -3.6 | 7.9 | |
+/-Cat | -7.0 | 5.8 | 11.4 | -0.5 | 4.1 | |
+/-B’mrk | - | -3.0 | 0.9 | -1.0 | 0.5 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 20/11/2024 | USD 68.05 | |
Day Change | 1.26% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0122379950 | |
Fund Size (Mil) 31/10/2024 | USD 14268.29 | |
Share Class Size (Mil) 20/11/2024 | USD 6666.73 | |
Max Initial Charge | 5.26% | |
Ongoing Charge 05/02/2024 | 1.78% |
Morningstar Research |
Analyst Report | 07/11/2024 Ramanand Kothari, Senior Analyst Morningstar, Inc |
A seasoned healthcare investor backed by a stable and well-resourced team underpins our conviction in BGF World Healthscience. The clean D share class retains its Morningstar Analyst Rating of Bronze, where other share classes range from Bronze... | |
Click here to read this analyst report on the underlying fund. |
Morningstar Pillars | |
---|---|
People | 24 |
Parent | 24 |
Process | 23 |
Performance | |
Price |
Investment Objective: BlackRock Global Funds - World Healthscience Fund A2 |
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Xiang Liu 01/06/2020 | ||
Erin Xie 01/04/2011 | ||
Inception Date 06/04/2001 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BlackRock Global Funds - World Healthscience Fund A2 | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 7.95 |
UnitedHealth Group Inc | Healthcare | 7.28 |
AbbVie Inc | Healthcare | 5.28 |
Boston Scientific Corp | Healthcare | 4.78 |
Novo Nordisk AS Class B | Healthcare | 4.66 |
Increase Decrease New since last portfolio | ||
BlackRock Global Funds - World Healthscience Fund A2 |